Despite significant treatment advancements in the management of multiple myeloma over the last 20 years, racial disparities in health care access and survival continue to exist. READ MORE
Results of a recent study showed that the prognostic implications of patient-specific and tumor biological features vary significantly across age-groups of patients with multiple myeloma.
A recent study found that a significant number of patients with multiple myeloma harbor potentially actionable oncogenic molecular alterations, prompting a need for novel precision medicine approaches.
A recent study found that continued therapy with a combination regimen until disease progression improves outcomes in patients with newly diagnosed multiple myeloma who are not eligible for ASCT.
The US Food and Drug Administration has expanded the indication for a drug to treat previously untreated follicular lymphoma.